Bortezomib in Treating Young Patients With Refractory or Recurrent Leukemia

This study has been completed.

Study NCT00077467 Information provided by National Cancer Institute (NCI)

First Received: February 10, 2004 Last Updated: December 14, 2010 History of Changes

No Study Results Posted on ClinicalTrials.gov for this Study

About Study Results Reporting on ClinicalTrials.gov

Study Status:	This study has been completed.
Estimated Study Completion Date:	No date given
Primary Completion Date:	March 2006 (Final data collection date for primary outcome measure)

Publications:

Horton TM, Pati D, Plon SE, Thompson PA, Bomgaars LR, Adamson PC, Ingle AM, Wright J, Brockman AH, Paton M, Blaney SM. A Phase 1 Study of the Proteasome Inhibitor Bortezomib in Pediatric Patients with Refractory Leukemia: a Children's Oncology Group Study. Clin Cancer Res. 2007 Mar 1;13(5):1516-22.

Horton TM, Thompson PA, Bomgaars LR, et al.: A phase I study of bortezomib (PS-341) in pediatric patients with relapsed or refractory leukemia: a Children's Oncology Group study. [Abstract] J Clin Oncol 24 (Suppl 18): A-9021, 507s, 2006.